Pharming Group NV
AEX:PHARM
Pharming Group NV
Operating Income
Pharming Group NV
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Income
-$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Income
-€30.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-6%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Income
-$177.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-15%
|
|
|
argenx SE
XBRU:ARGX
|
Operating Income
-$14m
|
CAGR 3-Years
66%
|
CAGR 5-Years
41%
|
CAGR 10-Years
-3%
|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Income
-$272.1m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Operating Income
-$43.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Operating Income?
Operating Income
-3.6m
USD
Based on the financial report for Dec 31, 2024, Pharming Group NV's Operating Income amounts to -3.6m USD.
What is Pharming Group NV's Operating Income growth rate?
Operating Income CAGR 1Y
83%
Over the last year, the Operating Income growth was 83%.
You don't have any saved screeners yet